PMID- 33072782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment.
PG  - 554134
LID - 10.3389/fmed.2020.554134 [doi]
LID - 554134
AB  - Lymphangioleiomyomatosis (LAM) is a rare systemic neoplastic disease that 
      exclusively happens in women. Studies focusing on LAM and tuberous sclerosis 
      complex (TSC) have made great progress in understanding the pathogenesis and 
      searching for treatment. The inactive mutation of TSC1 or TSC2 is found in 
      patients with LAM to activate the crucial mammalian target of rapamycin (mTOR) 
      signaling pathway and result in enhanced cell proliferation and migration. 
      However, it does not explain every step of tumorigenesis in LAM. Because 
      cessation of rapamycin would break the stabilization of lung function or improved 
      quality of life and lead to disease recurrent, continued studies on the 
      pathogenesis of LAM are necessary to identify novel targets and new treatment. 
      Researchers have found several aberrant regulations that affect the mTOR pathway 
      such as its upstream or downstream molecules and compensatory pathways in LAM. 
      Some therapeutic targets have been under study in clinical trials. New methods 
      like genome-wide association studies have located a novel gene related to LAM. 
      Herein, we review the current knowledge regarding pathogenesis and treatment of 
      LAM and summarize novel targets of therapeutic potential recently.
CI  - Copyright (c) 2020 Song, Cai, Yang, Xue, Wang, Mo, Zhu, Zhu, Ye and Jin.
FAU - Song, Xixi
AU  - Song X
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Cai, Hui
AU  - Cai H
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Yang, Chengyu
AU  - Yang C
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Xue, Xiaomin
AU  - Xue X
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Mo, Yuqing
AU  - Mo Y
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Zhu, Mengchan
AU  - Zhu M
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Zhu, Guiping
AU  - Zhu G
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Ye, Ling
AU  - Ye L
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Jin, Meiling
AU  - Jin M
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200924
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7542236
OTO - NOTNLM
OT  - lymphangioleiomyomatosis
OT  - mTOR
OT  - pathogenesis
OT  - target
OT  - treatment
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
PMCR- 2020/09/24
CRDT- 2020/10/19 05:59
PHST- 2020/04/21 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/19 05:59 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
PHST- 2020/09/24 00:00 [pmc-release]
AID - 10.3389/fmed.2020.554134 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Sep 24;7:554134. doi: 10.3389/fmed.2020.554134. 
      eCollection 2020.